Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19
Peter Chen, Ajay Nirula, Barry N. Heller, et al.
New England Journal of Medicine (2020) Vol. 384, Iss. 3, pp. 229-237
Open Access | Times Cited: 1347

Showing 26-50 of 1347 citing articles:

SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801
Angela Wahl, Lisa E. Gralinski, Claire Johnson, et al.
Nature (2021) Vol. 591, Iss. 7850, pp. 451-457
Open Access | Times Cited: 365
Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Obbina Abani, Ali Abbas, Fatima Abbas, et al.
The Lancet (2022) Vol. 399, Iss. 10325, pp. 665-676
Open Access | Times Cited: 354
Neutralizing antibody responses to SARS-CoV-2 in symptomatic COVID-19 is persistent and critical for survival
Stefania Dispinseri, Massimiliano Secchi, Maria Franca Pirillo, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 352
Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection
Emma S. Winkler, Pavlo Gilchuk, Jinsheng Yu, et al.
Cell (2021) Vol. 184, Iss. 7, pp. 1804-1820.e16
Open Access | Times Cited: 349
Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7
Pengfei Wang, Manoj S. Nair, Lihong Liu, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 320
Rapid generation of durable B cell memory to SARS-CoV-2 spike and nucleocapsid proteins in COVID-19 and convalescence
Gemma E. Hartley, Emily S.J. Edwards, Pei M. Aui, et al.
Science Immunology (2020) Vol. 5, Iss. 54
Open Access | Times Cited: 308
Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir
Sho Iketani, Hiroshi Mohri, Bruce Culbertson, et al.
Nature (2022) Vol. 613, Iss. 7944, pp. 558-564
Open Access | Times Cited: 306
Molecular mechanism of interaction between SARS-CoV-2 and host cells and interventional therapy
Qianqian Zhang, Rong Xiang, Shanshan Huo, et al.
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 300
Influenza virus and SARS-CoV-2: pathogenesis and host responses in the respiratory tract
Tim Flerlage, David F. Boyd, Victoria Meliopoulos, et al.
Nature Reviews Microbiology (2021) Vol. 19, Iss. 7, pp. 425-441
Open Access | Times Cited: 298
Lessons learned 1 year after SARS-CoV-2 emergence leading to COVID-19 pandemic
Kelvin Kai‐Wang To, Siddharth Sridhar, Kelvin Hei‐Yeung Chiu, et al.
Emerging Microbes & Infections (2021) Vol. 10, Iss. 1, pp. 507-535
Open Access | Times Cited: 297
A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus
William A. Fischer, Joseph J. Eron, Wayne Holman, et al.
Science Translational Medicine (2021) Vol. 14, Iss. 628
Open Access | Times Cited: 297
COVID-19 Transmission, Current Treatment, and Future Therapeutic Strategies
Vrishali S. Salian, Jessica Wright, Peter T. Vedell, et al.
Molecular Pharmaceutics (2021) Vol. 18, Iss. 3, pp. 754-771
Closed Access | Times Cited: 296
Lectins enhance SARS-CoV-2 infection and influence neutralizing antibodies
Florian A. Lempp, Leah Soriaga, Martin Montiel-Ruiz, et al.
Nature (2021) Vol. 598, Iss. 7880, pp. 342-347
Closed Access | Times Cited: 293
SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma
Constantinos Kurt Wibmer, Frances Ayres, Tandile Hermanus, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 283
Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations
Frauke Muecksch, Yiska Weisblum, Christopher O. Barnes, et al.
Immunity (2021) Vol. 54, Iss. 8, pp. 1853-1868.e7
Open Access | Times Cited: 281
Broadly neutralizing antibodies to SARS-CoV-2 and other human coronaviruses
Yanjia Chen, Xiaoyu Zhao, Hao Zhou, et al.
Nature reviews. Immunology (2022) Vol. 23, Iss. 3, pp. 189-199
Open Access | Times Cited: 272
Antibodies to watch in 2021
Hélène Kaplon, Janice M. Reichert
mAbs (2021) Vol. 13, Iss. 1
Open Access | Times Cited: 271
Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection
Deborah Cromer, Jennifer A. Juno, David S. Khoury, et al.
Nature reviews. Immunology (2021) Vol. 21, Iss. 6, pp. 395-404
Open Access | Times Cited: 258
Effect of Sotrovimab on Hospitalization or Death Among High-risk Patients With Mild to Moderate COVID-19
Anil Kumar Gupta, Yaneicy Gonzalez‐Rojas, Erick Stanley Petersen Juárez, et al.
JAMA (2022) Vol. 327, Iss. 13, pp. 1236-1236
Open Access | Times Cited: 254
Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7
Pengfei Wang, Manoj S. Nair, Lihong Liu, et al.
(2021)
Open Access | Times Cited: 253
Preexisting autoantibodies to type I IFNs underlie critical COVID-19 pneumonia in patients with APS-1
Paul Bastard, Elizaveta Orlova, Leila Sozaeva, et al.
The Journal of Experimental Medicine (2021) Vol. 218, Iss. 7
Open Access | Times Cited: 252
Delayed production of neutralizing antibodies correlates with fatal COVID-19
Carolina Lucas, Jon Klein, Maria E. Sundaram, et al.
Nature Medicine (2021) Vol. 27, Iss. 7, pp. 1178-1186
Open Access | Times Cited: 243
Emerging Variants of SARS-CoV-2 And Novel Therapeutics Against Coronavirus (COVID-19)
Abdul Aleem, Abdul Samad, Amy Slenker
(2021) Vol. 01, pp. 01-01
Closed Access | Times Cited: 242
The dual function monoclonal antibodies VIR-7831 and VIR-7832 demonstrate potent in vitro and in vivo activity against SARS-CoV-2
Andrea L. Cathcart, Colin Havenar‐Daughton, Florian A. Lempp, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 241
Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications
Ioannis P. Trougakos, Κimon Stamatelopoulos, Evangelos Terpos, et al.
Journal of Biomedical Science (2021) Vol. 28, Iss. 1
Open Access | Times Cited: 240

Scroll to top